Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer.

BACKGROUND Detection of circulating tumor cells (CTCs) in the peripheral blood of patients with primary breast cancer is associated with poor clinical outcome. Recent studies have found evidence for immunological influence on tumor cell dormancy. We therefore investigated the relationship between peripheral T-cells and CTCs, as immunological factors may contribute to the fate of CTCs. MATERIALS AND METHODS The peripheral blood immune status of 116 patients with primary breast cancer was analyzed by flow cytometry. Results were correlated with the presence of CTCs and clinicopathological parameters of these patients. RESULTS Appearance of CTCs was significantly associated with grade III tumors (p<0.05). Interestingly, CTC-positive patients presented with a significant increase of peripheral CD95(FAS)-positive T-helper cells. As immune response is regulated by CD95(APO-1/FAS)-CD95ligand interaction and tumor cells induce apoptosis via the CD95/CD95L (ligand) pathway, this might lead to tumor cell escape by apoptotic T-helper cells. CONCLUSION Absence of T-cell help at the time of priming may result in a loss of long-term antigen-activation of CD8 lymphocytes and could lead to an ineffective anti-tumor cell response. This might contribute to systemic immunosuppression and open the door for tumor cell dormancy.

[1]  Minghui Zhang,et al.  The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature , 2011, Breast Cancer Research and Treatment.

[2]  M. Pistillo,et al.  Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. , 2010, Anticancer research.

[3]  T. Fehm,et al.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells , 2009, Breast Cancer Research.

[4]  G. Kallergi,et al.  Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer , 2008, Clinical Cancer Research.

[5]  C. Sotiriou,et al.  Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. , 2007, Clinical breast cancer.

[6]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  O. Böcher,et al.  Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment , 2006, Molecular biotechnology.

[8]  C. Klein,et al.  Systemic Cancer Progression and Tumor Dormancy: Mathematical Models Meet Single Cell Genomics , 2006, Cell cycle.

[9]  Veit Zieglschmid,et al.  Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. , 2005, Anticancer research.

[10]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. North,et al.  Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. , 2005, Cancer letters.

[12]  M. Bevan,et al.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.

[13]  U. Demel,et al.  Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. , 2004, Journal of experimental & clinical cancer research : CR.

[14]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[15]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[16]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[17]  T. Whiteside,et al.  Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  I. Vlachonikolis,et al.  Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Whiteside,et al.  Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  H. Salih,et al.  Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance? , 2001, European journal of medical research.

[21]  M. Lotze,et al.  Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  B. Melichar,et al.  THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN/PACLITAXEL COMBINATION CHEMOTHERAPY , 2001, Immunopharmacology and immunotoxicology.

[23]  S. Narod,et al.  RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters , 2000, Breast Cancer Research and Treatment.

[24]  M. Beckmann,et al.  CD95 ligand expression as a mechanism of immune escape in breast cancer , 2000, Immunology.

[25]  H. Gudmundsdottir,et al.  Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. , 1999, Journal of immunology.

[26]  W. Urba,et al.  Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules , 1998 .

[27]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[28]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[29]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[30]  D. Loh,et al.  Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. , 1995, Journal of immunology.

[31]  J. Forman,et al.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes , 1982, The Journal of experimental medicine.

[32]  W. Tan,et al.  Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer , 2006 .

[33]  S. Ferrone,et al.  Mechanisms of tumor evasion. , 2005, Cancer treatment and research.